Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Amulirafusp alfa (IMM0306) is a novel cancer immunotherapy designed to target CD20-positive B-cell malignancies. It is a fusion protein combining a CD20 monoclonal antibody with the CD47 binding domain of SIRP alpha enabling it to simultaneously engage both CD20 and CD47 on cancer cells. This dual targeting enhances macrophage-mediated phagocytosis and natural killer cell activation promoting the immune system's ability to eliminate malignant B cells.
仅用于科研。不用于诊断过程。未经明确授权不得转售。